Search research articles
Contact Us
Filters
Showing results (51-60 of 208) with videos related to
Page
of 21
Sort By:
Clinical Pharmacology : Advances and Applications
|
August 17, 2022
Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response
Filip Stefanovic, Andres Gomez-Caminero, David M Jacobs, et al.
JAMA
|
November 5, 2014
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial
F Stephen Hodi, Sandra Lee, David F McDermott, et al.
Journal for Immunotherapy of Cancer
|
February 29, 2024
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy
Allison Betof Warner, Omid Hamid, Krishna Komanduri, et al.
EMBO Reports
|
December 11, 2024
Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Yuhao Shi, Amber McKenery, Melissa Dolan, et al.
Anti-Cancer Drugs
|
May 29, 2015
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies
Olivier Rixe, Igor Puzanov, Patricia M LoRusso, et al.
Journal for Immunotherapy of Cancer
|
August 17, 2019
The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018
Paolo A Ascierto, Lisa H Butterfield, Sandra Demaria, et al.
Journal of Translational Medicine
|
April 22, 2022
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021
Paolo A Ascierto, Lisa H Butterfield, Olivera J Finn, et al.
Future Oncology (London, England)
|
August 25, 2017
Challenges faced when identifying patients for combination immunotherapy
Marc S Ernstoff, Shipra Gandhi, Manu Pandey, et al.
Journal for Immunotherapy of Cancer
|
October 26, 2016
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Bridgette A Kanz, Megan H Pollack, Romany Johnpulle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2014
A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors
Igor Puzanov, Colin R Lindsay, Laura Goff, et al.
Page
of 21
Search research articles
Search
Showing results (51-60 of 208) with videos related to
Sort By:
Page
of 21
Clinical Pharmacology : Advances and Applications
|
August 17, 2022
Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response
Filip Stefanovic, Andres Gomez-Caminero, David M Jacobs, et al.
JAMA
|
November 5, 2014
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial
F Stephen Hodi, Sandra Lee, David F McDermott, et al.
Journal for Immunotherapy of Cancer
|
February 29, 2024
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy
Allison Betof Warner, Omid Hamid, Krishna Komanduri, et al.
EMBO Reports
|
December 11, 2024
Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Yuhao Shi, Amber McKenery, Melissa Dolan, et al.
Anti-Cancer Drugs
|
May 29, 2015
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies
Olivier Rixe, Igor Puzanov, Patricia M LoRusso, et al.
Journal for Immunotherapy of Cancer
|
August 17, 2019
The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018
Paolo A Ascierto, Lisa H Butterfield, Sandra Demaria, et al.
Journal of Translational Medicine
|
April 22, 2022
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021
Paolo A Ascierto, Lisa H Butterfield, Olivera J Finn, et al.
Future Oncology (London, England)
|
August 25, 2017
Challenges faced when identifying patients for combination immunotherapy
Marc S Ernstoff, Shipra Gandhi, Manu Pandey, et al.
Journal for Immunotherapy of Cancer
|
October 26, 2016
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Bridgette A Kanz, Megan H Pollack, Romany Johnpulle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2014
A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors
Igor Puzanov, Colin R Lindsay, Laura Goff, et al.
Page
of 21